We transform lives through pioneering treatments for metabolic, neurological, fibrotic, and gynecological disorders—driving discovery and delivering hope to patients when they need it most.
We persistently uncover revolutionary treatments for metabolic, neurological, fibrotic, and gynecological disorders – finding exceptional molecules where others have failed through relentless innovation and scientific precision.
Akeso Biopharma is a privately held virtual biotech company focused on developing novel therapies for unmet medical needs. Our lead molecule is a novel drug for MASH, by reducing inflammation and fibrosis progression. Our second asset in our pipeline is a novel drug for pre-term birth prevention.
Our flagship program, AD64, is designed to be potentially the best-in-class treatment for one of the world’s most unmet medical needs by promoting an anti-fibrotic pathway that reduces fibrosis and inhibits the progression of MASH.
Akeso begins Phase II clinical trials for anti-fibrotic therapy targeting MASH patients.
August 5, 2025